STUDY SUMMARY
Colon Cancer Model: J000101329
NSG™ mice engrafted with passage 4 tumors for model J000101329
were randomly assigned to one of these treatment groups:
- Control group (no treatment; N=5)
- Cisplatin (2 mg/kg; IV once per week for three times; N=5 )
- Olaparib (50 mg/kg; PO once daily for three weeks; N=5)
- Dabrafenib + Trametinib combination (30 mg/kg; PO once daily for three weeks + 0.6 mg/kg; PO once daily for three weeks; N=5)
- Dabrafenib + Trametinib + Cetuximab combination (30 mg/kg; PO once daily for three weeks + 0.6 mg/kg; PO once daily for three weeks + 10 mg/kg; IV twice weekly for three weeks; N=5)
Mice were monitored for tumor volume at least twice per week throughout the study period.
• Treatment groups
• Individual subjects / spider plot
• RECIST scores
• Waterfall plot
• TGI plot
• Protocols
Hide/show treatment groups
Hide/show treatment groups
Hide/show treatment groups